ETFs positioned on Ipsen

Name YTD change Weight AuM
+11.28% - 27,154 M€
+6.85% - 92 M€
+11.48% - 13 M€
+6.02% - 49 M€
+0.60% - 51 M€
+10.56% - 66 M€
+10.45% - 24,432 M€
+8.09% - 75 M€
+10.65% - 67 M€
+7.44% - 6 M€
+4.33% - 1,193 M€
+6.62% - 6,576 M€
+9.93% - 3,469 M€
+8.62% - 5,871 M€
0.00%4.67% 8 M€
+57.62%3.96% 215 M€
+9.68%3.25% 23 M€
+14.45%1.94% 31 M€
+8.58%1.94% 31 M€
+2.85%1.75% 574 M€
+10.96%1.54% 18 M€
+10.70%1.52% 17 M€
+11.22%1.48% 160 M€
0.00%1.05% 208 M€
0.00%1.05% 26 M€
+9.13%0.98% 125 M€
+7.81%0.87% 730 M€
+7.90%0.83% 55 M€
+7.67%0.83% 20 M€
+21.51%0.79% 1,260 M€
+11.98%0.78% 103 M€
+9.41%0.59% 140 M€
+0.73%0.58% 38 M€
+7.33%0.54% 51 M€
+8.88%0.53% 40 M€
+6.09%0.5% 23 M€
+9.22%0.47% 937 M€
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535